Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Neurogene Inc. (NGNE)
Company Research
Source: Business Wire
Company to host webcast to review data on November 11 at 4:30 p.m. ETLate-breaker poster to be presented during Child Neurology Society Meeting on November 12 NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will host a webcast to present interim efficacy data from the low-dose cohort of its ongoing Phase 1/2 clinical trial of NGN-401 gene therapy for pediatric patients with Rett syndrome on November 11, 2024 at 4:30 p.m. ET. Safety data from the low- and high-dose cohorts will also be shared.These data will also be presented in a late-breaking poster presentation during the 53rd Annual Child Neurology Society (CNS) Annual Meeting on November 12 at 12:30 p.m. PT in San Diego, CA.Neurogene’s Analyst and Investor Webcast/Conference CallThe live webcast and conference call information will be accessible from the Inv
Show less
Read more
Impact Snapshot
Event Time:
NGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGNE alerts
High impacting Neurogene Inc. news events
Weekly update
A roundup of the hottest topics
NGNE
News
- Neurogene Inc. (NASDAQ: NGNE) had its price target raised by analysts at Stifel Nicolaus from $44.00 to $60.00. They now have a "buy" rating on the stock.MarketBeat
- Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at BMO Capital Markets from $65.00 to $60.00. They now have an "outperform" rating on the stock.MarketBeat
- Neurogene Inc. (NASDAQ: NGNE) had its price target raised by analysts at Leerink Partners from $45.00 to $72.00. They now have an "outperform" rating on the stock.MarketBeat
- Neurogene Inc. (NASDAQ: NGNE) had its price target raised by analysts at HC Wainwright from $49.00 to $55.00. They now have a "buy" rating on the stock.MarketBeat
- Neurogene Inc. (NASDAQ: NGNE) had its price target raised by analysts at Robert W. Baird from $54.00 to $72.00. They now have an "outperform" rating on the stock.MarketBeat
NGNE
Earnings
- 8/9/24 - Miss
NGNE
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form 8-K
- 11/8/24 - Form SC
- NGNE's page on the SEC website